Beta Bionics (BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance -- HBSS

Hagens Berman issued a shareholder-solicitation notice for a securities class action against Beta Bionics covering purchasers between July 30, 2025 and February 24, 2026, with a lead plaintiff deadline of November 3, 2026. The complaint alleges management downplayed an FDA Form 483 on the iLet insulin delivery system while concealing thousands of safety complaints, including serious hypoglycemic events, culminating in an FDA warning letter published February 24, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.